Slide 1: SynAct Pharma AB EXPAND Study Update
INFLAMMATION RESOLUTION SynAct Pharma AB EXPAND Study Update September 13 2023
Slide 2: Forward Looking Statements
Forward Looking Statements Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except fo
Slide 3: Consistent activity seen in patients with evidence of active inflammation
Consistent activity seen in patients with evidence of active inflammation • Resomelagon treated patients with elevated CRP at baseline (> 3mg/L) exhibited consistent responsiveness over placebo at 12 weeks across all outcome measures ⁃ 70.6% of resomelagon treated patients achieved an ACR20 response
Slide 4: The EXPAND study – ACR20
The EXPAND study – ACR20 All pts Baseline hsCRP > 3 80 80 70 70 70,6 60 60 50 54,7 55,7 50 54,3 47,5 48,6 40 40 % % 42,9 38,2 30 35,3 30 20 23,7 20 22,9 21 10 10 9,8 9,5 10 8,1 0 0 2 weeks 4 weeks 8 weeks 12 weeks 2 weeks 4 weeks 8 weeks 12 weeks resomelagon (n=53) Placebo (n=61) resomelagon (n=34)
Slide 5: ACR Scores following weeks treatment
The EXPAND study - ACR Scores following 12 weeks treatment – All pts Baseline hsCRP > 3 80 ACR20 ACR50 ACR70 80 ACR20 ACR50 ACR70 70 70 71 60 60 50 55 56 50 Percentage (%) 54 Percentage (%) 40 40 30 30 20 20 10 18 21 20 15 4 3,3 10 0 3 3 0 Resomelagon (n=53) Placebo (n=61) Resomelagon (n=34) Placebo
Slide 6: The EXPAND study – Changes in Health Assessment Questionnaire (HAQ)
The EXPAND study – Changes in Health Assessment Questionnaire (HAQ) - All pts Baseline hsCRP > 3 2w 4w 8w 12w 2w 4w 8w 12w 0,00 0,00 -0,08 -0,10 -0,10 -0,12 -0,17 -0,20 -0,20 -0,26 -0,20 -0,22 -0,25 -0,30 -0,30 -0,30 -0,31 -0,37 -0,30 -0,42 -0,40 -0,40 -0,40 -0,45 -0,51 -0,50 -0,50 -0,60 -0,60 -0,64
Slide 7: % of patients reaching minimum clinical important difference (MCID) in HAQ score
% of patients reaching minimum clinical important difference (MCID) in HAQ score All pts Baseline hsCRP > 3 100% 100% * 80% 80% 85% 82% 74% 70% 74% 72% 60% 60% 63% 58% 57% 49% 50% 51% 40% 40% 42% 43% 36% 35% 20% 20% 0% 0% Resomelagon (n=53) Placebo (n=61) Resomelagon (n=34) Placebo (n=35) 2 weeks 4
Slide 8: The EXPAND study – Changes in CDAI
The EXPAND study – Changes in CDAI All pts Baseline hsCRP > 3 0,0 2w 4w 8w 12w 2w 4w 8w 12w 0,0 -5,0 -6,8 -5,0 -6,5 -8,5 -11,0 -10,0 -10,6 -10,0 -10,0 -13,1 -13,0 -14,1 -15,5 -15,0 -15,0 -16,5 -17,9 -18,6 -19,5 -20,6 -20,0 -20,0 -22,4 -25,0 -25,0 Resomelagon (n=53) Placebo (n=61) Resomelagon (n=34)
Slide 9: The EXPAND study – Changes in DAS28
The EXPAND study – Changes in DAS28 All pts Baseline hsCRP > 3 2w 4w 8w 12w 2w 4w 8w 12w 0,0 0,0 -0,2 -0,2 -0,4 -0,4 -0,5 -0,4 -0,6 -0,6 -0,6 -0,6 -0,8 -0,8 -0,8 -0,8 -0,9 -0,9 -1,0 -1,1 -1,0 -1,1 -1,2 -1,2 -1,2 -1,4 -1,5 -1,5 -1,4 -1,4 -1,4 -1,6 -1,6 -1,7 -1,8 -1,8 Resomelagon (n=53) Placebo (n=61)
Slide 10: Consistent activity seen in patients with evidence of active inflammation
Consistent activity seen in patients with evidence of active inflammation • Resomelagon treated patients with elevated CRP at baseline (> 3mg/L) exhibited consistent responsiveness over placebo at 12 weeks across all outcome measures ⁃ 70.6% of resomelagon treated patients achieved an ACR20 response
Slide 11: Upcoming news flow
Upcoming news flow Q3 2023 Q4 2023 H1 2024 ü September: Topline October: Topline Initiation of Resolve results from Expand results from Part A Part B ü Sub analysis from Resolve Expand and secondary Initiation of Phase I variables More results from TXP-11 Expand More pipeline updates More results fr